Simon Morriss - Genetic Technologies Chief Officer
| GTG Stock | 0.04 0.00 0.00% |
Executive
Simon Morriss is Chief Officer of Genetic Technologies
| Age | 51 |
| Address | 321 Chapel Street, Prahran, VIC, Australia, 3181 |
| Phone | 61 3 8412 7000 |
| Web | https://genetype.com |
Genetic Technologies Management Efficiency
The company has return on total asset (ROA) of (0.6293) % which means that it has lost $0.6293 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.8498) %, meaning that it generated substantial loss on money invested by shareholders. Genetic Technologies' management efficiency ratios could be used to measure how well Genetic Technologies manages its routine affairs as well as how well it operates its assets and liabilities. Non Current Liabilities Other is likely to gain to about 1.2 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 2 M in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| BBus BCom | Mayfield Childcare | 47 | |
| Michelle Scott | Mayfield Childcare | N/A | |
| Christopher CPA | Mayfield Childcare | N/A | |
| Francis Truong | Mayfield Childcare | N/A | |
| Konstanty Bialkowski | EMvision Medical Devices | N/A | |
| Robert Tiller | EMvision Medical Devices | N/A | |
| Jon Dusting | 4Dmedical | N/A | |
| MBA BS | 4Dmedical | N/A | |
| Scott Conway | Mayfield Childcare | N/A | |
| Aidan BE | 4Dmedical | N/A | |
| Merricc EdgarHughes | EMvision Medical Devices | N/A | |
| Simone Lethaus | Mayfield Childcare | N/A | |
| Michael Curtis | 4Dmedical | N/A | |
| Naomi Lawrie | 4Dmedical | N/A | |
| Christian Wight | EMvision Medical Devices | N/A | |
| Ashok Naveinthiran | Mayfield Childcare | ||
| Simon Glover | 4Dmedical | N/A | |
| Simon Beake | Australian Unity Office | N/A | |
| Matt Tucker | 4Dmedical | N/A | |
| Rachael Tenkaten | 4Dmedical | N/A | |
| Beth Plunkett | 4Dmedical | N/A | |
Management Performance
| Return On Equity | -1.85 | ||||
| Return On Asset | -0.63 |
Genetic Technologies Leadership Team
Elected by the shareholders, the Genetic Technologies' board of directors comprises two types of representatives: Genetic Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genetic. The board's role is to monitor Genetic Technologies' management team and ensure that shareholders' interests are well served. Genetic Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genetic Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin Camilleri, Chief EasyDNA | ||
| Mark Ziirsen, CFO Secretary | ||
| CPA BCom, Chief Secretary | ||
| Erika Spaeth, Director Affairs | ||
| AGIA BCom, CFO Sec | ||
| Bus FCI, Consultant | ||
| Simon Morriss, Chief Officer | ||
| Richard Allman, Chief Officer | ||
| Carl BSc, Chief Officer |
Genetic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genetic Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.85 | ||||
| Return On Asset | -0.63 | ||||
| Profit Margin | (1.24) % | ||||
| Operating Margin | (1.13) % | ||||
| Current Valuation | 5.53 M | ||||
| Shares Outstanding | 145.42 M | ||||
| Shares Owned By Insiders | 10.45 % | ||||
| Price To Book | 3.10 X | ||||
| Price To Sales | 0.59 X | ||||
| Revenue | 7.66 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Genetic Stock Analysis
When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.